CN106536510A - 吡啶取代的2‑氨基吡啶类蛋白激酶抑制剂 - Google Patents

吡啶取代的2‑氨基吡啶类蛋白激酶抑制剂 Download PDF

Info

Publication number
CN106536510A
CN106536510A CN201580039739.6A CN201580039739A CN106536510A CN 106536510 A CN106536510 A CN 106536510A CN 201580039739 A CN201580039739 A CN 201580039739A CN 106536510 A CN106536510 A CN 106536510A
Authority
CN
China
Prior art keywords
acid
compound
type
salt
pharmaceutical acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201580039739.6A
Other languages
English (en)
Other versions
CN106536510B (zh
Inventor
龚峰
李新路
赵锐
张喜全
许新合
刘希杰
校登明
韩永信
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capital Pharmaceutical Holdings Beijing Co ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Shouyao Holdings Beijing Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd, Shouyao Holdings Beijing Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN106536510A publication Critical patent/CN106536510A/zh
Application granted granted Critical
Publication of CN106536510B publication Critical patent/CN106536510B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本发明公开了作为蛋白激酶抑制剂的吡啶取代的2‑氨基吡啶衍生物的药学上可接受酸的盐、其制备方法、其药物组合物及其在治疗和/或与蛋白激酶有关疾病中的用途。

Description

PCT国内申请，说明书已公开。

Claims (25)

  1. PCT国内申请，权利要求书已公开。
CN201580039739.6A 2014-07-31 2015-07-31 吡啶取代的2-氨基吡啶类蛋白激酶抑制剂 Active CN106536510B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2014103713443 2014-07-31
CN201410371344 2014-07-31
PCT/CN2015/085727 WO2016015676A1 (zh) 2014-07-31 2015-07-31 吡啶取代的2-氨基吡啶类蛋白激酶抑制剂

Publications (2)

Publication Number Publication Date
CN106536510A true CN106536510A (zh) 2017-03-22
CN106536510B CN106536510B (zh) 2019-04-26

Family

ID=55216786

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580039739.6A Active CN106536510B (zh) 2014-07-31 2015-07-31 吡啶取代的2-氨基吡啶类蛋白激酶抑制剂

Country Status (6)

Country Link
US (1) US9981946B2 (zh)
EP (1) EP3176160B1 (zh)
JP (1) JP6581180B2 (zh)
CN (1) CN106536510B (zh)
ES (1) ES2762641T3 (zh)
WO (1) WO2016015676A1 (zh)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112294813A (zh) * 2019-07-30 2021-02-02 正大天晴药业集团股份有限公司 喹啉衍生物在治疗脊索瘤中的用途
CN112336726A (zh) * 2019-08-09 2021-02-09 正大天晴药业集团股份有限公司 治疗结直肠癌的联用药物组合物
CN114173785A (zh) * 2019-08-01 2022-03-11 正大天晴药业集团股份有限公司 用于治疗非小细胞肺癌的氨基吡啶衍生物
CN115487188A (zh) * 2018-03-14 2022-12-20 正大天晴药业集团股份有限公司 治疗鼻咽癌的喹啉衍生物
CN114173785B (zh) * 2019-08-01 2024-10-25 正大天晴药业集团股份有限公司 用于治疗非小细胞肺癌的氨基吡啶衍生物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10385038B2 (en) * 2015-07-30 2019-08-20 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pyridine substituted 2-aminopyridine protein kinase inhibitor crystal
WO2021219137A1 (zh) * 2020-04-30 2021-11-04 正大天晴药业集团股份有限公司 用于治疗met基因异常疾病的氨基吡啶衍生物
CN113754579A (zh) * 2020-06-01 2021-12-07 正大天晴药业集团股份有限公司 一种吡啶衍生物的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006021886A1 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
CN104968654A (zh) * 2013-02-02 2015-10-07 正大天晴药业集团股份有限公司 取代的2-氨基吡啶类蛋白激酶抑制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1786785T3 (pl) 2004-08-26 2010-08-31 Pfizer Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe
EP2265270A1 (en) 2008-02-04 2010-12-29 OSI Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
EP2566858A2 (en) 2010-05-04 2013-03-13 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
RU2598849C2 (ru) 2011-02-24 2016-09-27 Цзянсу Хэнсох Фармасьютикал Ко., Лтд. Содержащие фосфор соединения в качестве ингибиторов протеинкина3
CN102718745A (zh) 2011-03-30 2012-10-10 中国科学院上海药物研究所 新型胺基吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
CN103965168A (zh) * 2013-02-02 2014-08-06 正大天晴药业集团股份有限公司 芳基、杂芳基取代的2-氨基吡啶类蛋白激酶抑制剂
CN104650049B (zh) 2013-08-28 2018-06-08 广东东阳光药业有限公司 取代的吡啶化合物及其使用方法和用途
US10385038B2 (en) * 2015-07-30 2019-08-20 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pyridine substituted 2-aminopyridine protein kinase inhibitor crystal

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006021886A1 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
CN104968654A (zh) * 2013-02-02 2015-10-07 正大天晴药业集团股份有限公司 取代的2-氨基吡啶类蛋白激酶抑制剂

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115487188A (zh) * 2018-03-14 2022-12-20 正大天晴药业集团股份有限公司 治疗鼻咽癌的喹啉衍生物
CN115487188B (zh) * 2018-03-14 2024-05-14 正大天晴药业集团股份有限公司 治疗鼻咽癌的喹啉衍生物
CN112294813A (zh) * 2019-07-30 2021-02-02 正大天晴药业集团股份有限公司 喹啉衍生物在治疗脊索瘤中的用途
CN114173785A (zh) * 2019-08-01 2022-03-11 正大天晴药业集团股份有限公司 用于治疗非小细胞肺癌的氨基吡啶衍生物
CN114173785B (zh) * 2019-08-01 2024-10-25 正大天晴药业集团股份有限公司 用于治疗非小细胞肺癌的氨基吡啶衍生物
CN112336726A (zh) * 2019-08-09 2021-02-09 正大天晴药业集团股份有限公司 治疗结直肠癌的联用药物组合物

Also Published As

Publication number Publication date
US9981946B2 (en) 2018-05-29
EP3176160A1 (en) 2017-06-07
CN106536510B (zh) 2019-04-26
EP3176160A4 (en) 2017-12-06
ES2762641T3 (es) 2020-05-25
JP6581180B2 (ja) 2019-09-25
WO2016015676A1 (zh) 2016-02-04
US20170226084A1 (en) 2017-08-10
EP3176160B1 (en) 2019-09-18
JP2017521475A (ja) 2017-08-03

Similar Documents

Publication Publication Date Title
CN106536510A (zh) 吡啶取代的2‑氨基吡啶类蛋白激酶抑制剂
AU2014211856C1 (en) Substituted 2-aminopyridine protein kinase inhibitor
US11352341B2 (en) 2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof
CN106928150A (zh) 丙烯酰胺苯胺衍生物及其药学上的应用
JP7531595B2 (ja) ピリド［３，４－ｄ］ピリミジン誘導体およびこれを含む治療用薬学組成物
CN107698603B (zh) 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
CN106432202B (zh) 喹唑啉类衍生物及其应用
KR101301533B1 (ko) 암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체
JP7427098B2 (ja) タンパク質キナ－ゼ阻害活性を有する７－アミノ－３，４－ジヒドロピリミドピリミジン－２－オン誘導体およびこれを含む治療用薬学組成物
US20240025908A1 (en) Compound used as kinase inhibitor and use thereof
CN109575045B (zh) 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
CN114630819B (zh) 用于预防或治疗癌症的苯甲酰胺衍生物、其制备方法以及包含其作为活性成分的药物组合物
TW201704226A (zh) 吡啶取代的２－氨基吡啶類蛋白激酶抑制劑的結晶
EP3152205A1 (en) 1h-1,8- naphthyridin-2ones as anti proliferative compounds
CN106146468B (zh) 吡啶酮类蛋白激酶抑制剂
CN112300145A (zh) 一类靶向stat3双功能磷酸化位点的三芳香环类化合物及其应用
KR102133569B1 (ko) 신규한 피롤로[2,3-d]피리미딘-4-온 유도체 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
CN113493436B (zh) 胺基取代吡啶衍生物及其制法和药物组合物与用途
KR102685187B1 (ko) Alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20190523

Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Co-patentee after: Lianyungang Runzhong Pharmaceutical Co.,Ltd.

Patentee after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Co-patentee after: Capital Pharmaceutical Holdings (Beijing) Co., Ltd.

Address before: 222062 Yuzhou South Road, Haizhou District, Lianyungang, Jiangsu 369

Co-patentee before: Lianyungang Runzhong Pharmaceutical Co.,Ltd.

Patentee before: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Co-patentee before: Beijing Centaurus Biopharma Technology Co., Ltd.

CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Patentee after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Patentee after: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd.

Patentee after: Capital Pharmaceutical Holdings (Beijing) Co.,Ltd.

Address before: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Patentee before: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Patentee before: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd.

Patentee before: Shouyao holding (Beijing) Co.,Ltd.